Oxidized LDL activates Fas-mediated endothelial cell apoptosis

Journal of Clinical Investigation

Volumn 102, Issue 9, 1998, Pages 1682-1689

  Sata, Masataka ^a   Walsh, Kenneth ^a,b,c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY   (United States)

^c ST ELIZABETH'S MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Endothelium; Fas; Fas ligand; Oxidized LDL

Indexed keywords

DNA FRAGMENT; FAS ANTIGEN; FAS LIGAND; LYSOPHOSPHATIDYLCHOLINE; NEUTRALIZING ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CAROTID ARTERY; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; VASCULAR ENDOTHELIUM;

EID: 0032211819     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI3531     Document Type: Article

References (59)

1. Scandinavian Simvastatin Survival Study Group. 1994. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1383-1389.
2. Steinberg, D. 1997. Low density lipoprotein oxidation and its pathological significance. J. Biol. Chem. 272:20963-20966.
3. Ylä-Herttuala, S., W. Palinski, M.E. Rosenfeld, S. Parthasarathy, T.E. Carew, S.W. Butler, J.L. Witztum, and D. Steinberg. 1989. Evidence for the presence of oxidatively modified LDL in atherosclerotic lesions of rabbit and man. J. Clin. Invest. 84:1086-1095.
4. Haberland, M.E., D. Fong, and L. Cheng. 1988. Malondialdehyde altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science. 241:215-218.
5. Kugiyama, K., S.A. Kerns, J.D. Morrisett, R. Roberts, and P.D. Henry. 1990. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature. 344:160-162.
6. Murugesan, G., and P.L. Fox. 1996. Role of lysophosphatidylcholine in the inhibition of endothelial cell motility by oxidized low density lipoprotein. J. Clin. Invest. 97:2736-2744.
7. Kume, N., M.I. Cybulsky, and M.A.J. Gimbrone. 1992. Lysophosphatidylcholine, a component of atherogenic lipoprotein, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J. Clin. Invest. 90:1138-1144.
8. Escargueil-Blanc, I., O. Meilhac, M.-T. Pieraggi, J.-F. Arnal, R. Salvayre, and A. Negre-Salvayre. 1997. Oxidized LDLs induce massive apoptosis of cultured human endothelial cells through a calcium-dependent pathway. Arterioscler Thromb Vasc Biol. 17:331-339.
9. Dimmeler, S., J. Haendeler, J. Galle, and A.M. Zeiher. 1997. Oxidized low-density lipoprotein induces apoptosis of human endothelial cells by activation of CPP32-like proteases. Circulation. 95:1760-1763.
10. Juckett, M.S., J. Balla, G. Balla, J. Jessurun, H.S. Jacob, and G.M. Vercellotti. 1995. Ferritin protects endothelial cells from oxidized low density lipoprotein in vitro. Am. J. Pathol. 147:782-789.
11. Harada-Shiba, M., M. Kinoshita, H. Kamido, and K. Shimokado. 1998. Oxidized low density lipoprotein induces apoptosis in cultured human umbilical vein endothelial cells by common and unique mechanisms. J. Biol. Chem. 273: 9681-9687.
12. Nagata, S., and P. Golstein. 1995. The Fas death factor. Science. 267: 1449-1456.
13. Griffith, T.S., T. Brunner, S.M. Fletcher, D.R. Green, and T.A. Ferguson. 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 270:1189-1192.
14. Bellgrau, D., D. Gold, H. Selawry, J. Moore, A. Franzusoff, and R.C Duke. 1995. A role of CD95 ligand in preventing graft rejection. Nature. 377:630-632.
15. Hahne, M., D. Rimoldi, M. Schröter, P. Romero, M. Schreier, L.E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, J.-C. Cerottini, and J. Tschopp. 1996. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science. 274:1363-1366.
16. Strand, S., W.J. Hofman, H. Hug, M. Müller, G. Otto, D. Strand, S.M. Mariani, W. Stremmel, P.H. Krammer, and P.R. Galle. 1996. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand expressing tumor cells-A mechanism of immune evasion? Nat. Med. 2:1361-1366.
17. Niehans, G.A., T. Brunner, S.P. Frizelle, J.C. Liston, C.T. Salerno, D.J. Knapp, D.R. Green, and R.A. Kratzke. 1997. Human lung carcinomas express Fas ligand. Cancer Res. 57:1007-1012.
18. Sata, M., and K. Walsh. 1998. TNFα regulation of Fas ligand expression on endothelium modulates leukocyte infiltration of the blood vessel wall. Nat. Med. 4:415-420.
19. Sata, M., H. Perlman, D.A. Muruve, M. Silver, M. Ikebe, T.A. Libermann, P. Oettgen, and K. Walsh. 1998. Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response. Proc. Natl. Acad. Sci. USA. 95:1213-1217.
20. Ross, R. 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:801-809.
21. Mach, F., U. Schonbeck, G.K. Sukhova, E. Atkinson, and P. Libby. 1998. Reduction of atherosclerosis in mice by inhibition of CD40 signaling. Nature. 394:200-203.
22. + T cells infiltrate lesions of apolipoprotein-E-deficient mice. Am. J. Pathol. 149:359-366.
23. Liao, F., J.A. Berliner, M. Mehrabian, M. Navab, L. Demer, A.J. Lusis, and A.M. Fogelman. 1991. Minimally modified low density lipoprotein is biologically active in vivo in mice. J. Clin. Invest. 87:2253-2257.
24. Tanaka, M., T. Suda, K. Haze, N. Nakamura, K. Sato, F. Kimura, K. Motoyoshi, M. Mizuki, S. Tagawa, S. Ohga, K. Hatake, A.H. Drummond, and S. Nagata. 1996. Fas ligand in human serum. Nat. Med. 2:317-322.
25. Merrick, A.F., L.D. Shewring, S.A. Cunningham, K. Gustafsson, and W. Fabre. 1997. Organ culture of arteries for experimental studies of vascular endothelium in situ. Transplant Immunol. 5:3-9.
26. Kiener, P.A., P.M. Davis, G.C. Starling, C. Mehlin, S.J. Klebanoff, J.A. Ledbetter, and W.C. Liles. 1997. Differential induction of apoptosis by Fas-Fas ligand interactions in human monocytes and macrophages. J. Exp. Med. 185: 1511-1516.
27. Chow, S.-E., R.-S. Lee, S.H. Shih, and J.-K. Chen. 1998. Oxidized LDL promotes vascular endothelial cell pinocytosis via a prooxidation mechanism. FASEB (Fed. Am. Soc. Exp. Biol.) J. 12:823-830.
28. Van Berkel, T.J.C., Y.B. DeRijke, and J.K. Kruijt. 1991. Different fate in vivo of oxidatively modified low density lipoprotein and acetylated low density lipoprotein in rats. J. Biol. Chem. 266:2282-2289.
29. Sawamura, T., N. Kume, T. Aoyama, H. Moriwaki, H. Hoshikawa, Y. Aibe, T. Tanaka, S. Miwa, Y. Katsura, T. Kita, and T. Masaki. 1997. An endothelial receptor for oxidized low-density lipoprotein. Nature. 386:73-77.
30. Berliner, J.A., M.C. Territo, A. Sevanian, S. Ramin, J.A. Kim, B. Bamshad, M. Esterson, and A.M. Fogelman. 1990. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J. Clin. Invest. 85: 1260-1266.
31. Stein, O., and Y. Stein. 1980. Bovine aortic endothelial cells display macrophage-like properties towards acetylated [I-125]-labeled low density lipoprotein. Biochem. Biophys. Acta. 620:631-635.
32. Sugiyama, S., K. Kugiyama, M. Ohgushi, K. Fujimoto, and H. Yasue. 1994. Lysophosphatidylcholine in oxidized low-density lipoprotein increases endothelial susceptibility to polymorphonuclear leukocyte-induced endothelial dysfunction in porcine coronary arteries. Circ. Res. 74:565-575.
33. Sue, I., I. Escargueil-Blanc, M. Troly, R. Salvayre, and A. Negre-Salvayre. 1997. HDL and ApoA prevent cell death of endothelial cells induced by oxidized LDL. Arterioscler. Thromb. Vasc. Biol. 17:2158-2166.
34. Kennedy, S.G., A.J. Wagner, S.D. Conzen, J. Jordan, A. Bellacosa, P.N. Tsichlis, and N. Hay. 1997. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev. 11:710-713.
35. Galle, J., P. Stunz, P. Schollmeyer, and C. Wanner. 1995. Oxidized LDL and lipoprotein(a) stimulate renin release of juxtaglomerular cells. Kidney Int. 47:45-52.
36. Dimmeler, S., J. Haendeler, J. Galle, and A.M. Zeiher. 1997. Oxidized low-density lipoprotein induces apoptosis of human endothelial cells by activation of CPP32-like proteases. Circulation. 95:1760-1763.
37. Leeuwenburgh, C., J.E. Rasmussen, F.F. Hsu, D.M. Mueller, S. Pennathur, and J.W. Heinecke. 1997. Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques. J. Biol. Chem. 272:3520-3526.
38. Tamai, O., H. Matsuoka, H. Itabe, Y. Wada, K. Kohno, and T. Imaizumi. 1996. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation. 95:76-82.
39. Palinski, W., S. Horkko, E. Miller, U.P. Steinbrecher, H.C. Powell, L.K. Curtiss, and J.L. Witztum. 1996. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J. Clin. Invest. 98:800-814.
40. Leppanen, P., J.S. Luoma, H.M. Hofker, L.M. Havekes, and S. Yla-Herttuala. 1998. Characterization of atherosclerotic lesions in apo E3-leiden transgenic mice. Atherosclerosis. 136:147-152.
41. Rodriguez, I., K. Matsuura, K. Khatib, J.C. Reed, S. Nagata, and P. Vassalli. 1996. A bcl-2 transgene expressed in hepatocytes protects mice from fulminant liver destruction but not from rapid death induced by anti-Fas antibody injection. J. Exp. Med. 183:1031-1036.
42. Lacronique, V., A. Mignon, M. Fabre, B. Viollet, N. Rouquet, T. Molina, A. Porteu, A. Henrion, D. Bouscary, P. Varlet, V. Joulin, and A. Kahn. 1996. Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nat. Med. 2:80-86.
43. Itoh, N., Y. Tsujimoto, and S. Nagata. 1993. Effect of bcl-2 on Fas antigen-mediated cell death. J. Immunol. 151:621-627.
44. Strasser, A., A.W. Harris, D.C.S. Huang, P.H. Krammer, and S. Cory. 1995. Bcl-2 and Fas/APO-1 regulates distinct pathways to lymphocyte apoptosis. EMBO (Eur. Mol. Biol. Organ.) J. 14:6136-6147.
45. Rehemtulla, A., C.A. Hamilton, A.M. Chinnaiyan, and V.M. Dixit. 1997. Ultraviolet radiation-induced apoptosis is mediated by activation of CD-95 (Fas/APO-1). J. Biol. Chem. 272:25783-25786.
46. Irmler, M., M. Thome, M. Hahne, P. Schneider, K. Hofmann, V. Steiner, J.-L. Bodmer, M. Schroter, K. Burns, C. Mattmann, D. Rimoldi, L. French, and J. Tschopp. 1997. Inhibition of death receptor signals by cellular FLIP. Nature. 388:190-195.
47. Hu, S., C. Vincenz, J. Ni, R. Gentz, and V.M. Dixit. 1997. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1 and CD-95-induced apoptosis. J. Biol. Chem. 272:17255-17257.
48. Srinivasula, S.M., M. Ahmad, S. Otilie, F. Bullrich, S. Banks, T. Fernandes-Alnemri, C.M. Croce, G. Litwack, K.J. Tomaselli, R.C. Armstrong, and E.S. Alnemri. 1997. FLAME-1, a novel FADD-like anti-apoptotic molecules that regulates Fas/TNFR1-induced apoptosis. J. Biol. Chem. 272:18542-18545.
49. Shu, H.B., D.R. Halpin, and D.V. Goeddel. 1997. Casper is a FADD-and caspase-related inducer of apoptosis. Immunity. 6:751-763.
50. Han, D.K.M., P.M. Chaudhary, M.E. Wright, C. Friedman, B.J. Trask, R.T. Riedel, D.G. Baskin, S.M. Schwartz, and L. Hood. 1997. MRIT, a novel death-effector domain-containing protein, interacts with caspases and BclXL and initiates cell death. Proc. Natl. Acad. Sci. USA. 94:11333-11338.
51. Okura, T., L. Gong, T. Kamitani, T. Wada, I. Okura, C.F. Wei, H.M. Chang, and T.H. Yeh. 1996. Protection against Fas/APO-1 and tumor necrosis factor-mediated cell death by a novel protein, Sentrin. J. Immunol. 157:4277-4281.
52. Maria, R.D., L. Lenti, F. Malisan, F. d'Agostino, B. Tomassini, A. Zeuner, M.R. Rippo, and R. Testi. 1997. Requirement for GD3 ganglioside in CD95-and ceramide-induced apoptosis. Science. 1997:1652-1655.
53. Melino, G., F. Bernassola, R.A. Knight, M.T. Corasaniti, G. Nistico, and A. Finazzi-Agro. 1997. S-nitrosylation regulates apoptosis. Nature. 388:432-433.
54. Mannick, J.B., X.Q. Miao, and J.S. Stamler. 1997. Nitric oxide inhibits Fas-induced apoptosis. J. Biol. Chem. 272:24125-24128.
55. Muller, M., S. Strand, H. Hug, E.-M. Heinemann, H. Walczak, W.J. Hofmann, W. Stremmel, P.H. Krammer, and P.R. Galle. 1997. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ ligand system and involves activation of wild-type p53. J. Clin. Invest. 99:403-413.
56. Hueber, A.-O., M. Zornig, D. Lyon, T. Suda, S. Nagata, and G.I. Evan. 1997. Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science. 278:1305-1309.
57. Friesen, C., I. Herr, H. Krammer, and K.-M. Debatin. 1996. Involvement of the CD95 (Apo-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med. 2:574-577.
58. Reap, E.A., K. Roof, K. Maynor, M. Borrero, J. Booker, and P. Cohen. 1997. Radiation and stress-induced apoptosis: a role for Fas/Fas ligand interaction. Proc. Natl. Acad. Sci. USA. 94:5750-5755.
59. Klas, C., K.-M. Debatin, R.R. Jonker, and P.H. Krammer. 1993. Activation interferes with the APO-1 pathway in mature human T cells. Int. Immunol. 5:625-630.